17. Liau KM, Lee YY, Chen CK, et al. An open-label pilot study to assess the efficacy and safety of virgin coconut oil in reducing visceral adiposity.
18. DeLany JP, Windhauser MM, Champagne CM, et al. Differential oxidation of individual dietary fatty acids in humans.
19. Lasekan JB, Rivera J, Hirvonen MD, et al. Energy expenditure in rats maintained with intravenous or intragastric infusion of total parenteral nutrition solutions containing medium- or long-chain triglyceride emulsions.
20. DeLany JP, Windhauser MM, Champagne CM, et al. Differential oxidation of individual dietary fatty acids in humans.
21. Там же.
22. Leyton J, Drury PJ, Crawford MA. Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat.
23. Lasekan JB, Rivera J, Hirvonen MD, et al. Energy expenditure in rats maintained with intravenous or intragastric infusion of total parenteral nutrition solutions containing medium- or long-chain triglyceride emulsions.
24. McCarty MF, DiNicolantonio JJ. Lauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pat hogenicit y.
25. von Schacky C. Cardiovascular disease prevention and treatment.
26. Там же.
27. Bunea R, El Farrah K, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia.
28. Schuchardt JP, Schneider I, Meyer H, et al. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations- a comparative bioavailability study of fish oil vs. krill oil.
29. Neubronner J, Schuchardt JP, Kressel G, et al. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters.
30. Dyerberg J, Madsen P, Moller JM, et al. Bioavailability of marine n-3 fatty acid formulations.
31. Krill [Интернет].
32. Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers.
33. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.
34. Alakbarzade V, Hameed A, Quek DQ, et al. A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome.
35. Guemez-Gamboa A, Nguyen LN, Yang H, et al. Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome.
36. Nishida Y, Yamashita E, Miki W, et al. Quenching activities of common hydrophilic and lipophilic antioxidants against singlet oxygen using chemiluminescence detection system.
37. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
38. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.
39. Alakbarzade V, Hameed A, Quek DQ, et al. A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome.
40. Guemez-Gamboa A, Nguyen LN, Yang H, et al. Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome.
41. MSC labelled Aker Biomarine krill products are from a sustainable and wellmanager fishery [Internet. Marine Stewardship Counci. 2018 Mar 27. Доступно по ссылке http://www.msc.org/newsroom/news/msc-labelled-aker-biomarine-krillproducts-are-from-a-sustainable-and-well-managed-fishery.